Dr. Serbina joined the TB Alliance in January 2019 as a Project Leader, Biology. Prior to joining TB Alliance, Dr. Serbina spent six years at Elusys Therapeutics where she led non clinical activities that supported US regulatory BLA submissions for a monoclonal anthrax antitoxin approved under FDA’s Animal Rule. Dr. Serbina also spent some time at Celgene where she led translational immune biomarker initiative across multiple myeloma trials.
Prior to joining Elusys, Dr. Serbina conducted extensive academic research in the infectious disease area encompassing research in tuberculosis, listeriosis and aspergillosis. Dr. Serbina spent nine years at the Memorial Sloan-Kettering Cancer Center as a post-doctoral fellow and senior research scientist in the laboratory of Dr. Eric Pamer where she elucidated host-pathogen interactions triggering the onset of inflammation during microbial infection.
Dr. Serbina received her PhD in immunology from the University of Pittsburgh where she studied immune protection in the murine model of acute and latent TB infection in the laboratory of Dr. JoAnne Flynn. Dr. Serbina has an extensive publication record in leading peer-reviewed scientific journals and authored book chapters and subject matter expert reviews in the areas of immunology and infectious disease.